IDOV-SAFE

BIOLOGICAL2 trials

Sponsors

Fudan University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Advanced Malignant Solid TumorAdvanced Solid TumorsMetastatic Solid TumorsRare Malignant Neoplasm

Early Phase 1

Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

RecruitingNCT06718946

Fudan UniversityAdvanced Malignant Solid Tumor

Start: 2024-12-10End: 2027-12-31Target: 38Updated: 2025-02-06

Phase 1

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Not yet recruitingNCT07307053

Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdvanced Solid Tumors, Metastatic Solid Tumors, Rare Malignant Neoplasm

Start: 2026-01-01End: 2031-01-31Target: 600Updated: 2025-12-29